Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
Louka E. et al, (2021), Journal of Experimental Medicine, 218
LARP1 isoform expression in human cancer cell lines.
Schwenzer H. et al, (2021), RNA Biol, 18, 237 - 247
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
Herrera AF. et al, (2021), CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19, 13 - 14
A source of hope for platinum-resistant ovarian cancer?
Blagden SP. and Nicum S., (2021), Lancet, 397, 254 - 256
Tumour gene expression signature in primary melanoma predicts long-term outcomes
Garg M. et al, (2021), Nature Communications
Application of Single Cell Approaches to Study MPN biology
MEAD A., (2021), Hematology / Oncology Clinics of North America
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S. et al, (2021), Future oncology (London, England)
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction.
Smith EM. et al, (2021), Nucleic Acids Res, 49, 458 - 478
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD. et al, (2021), J Clin Oncol, 39, 145 - 154
The Oxford Classic links epithelial-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers
AHMED A. et al, (2021), Clinical Cancer Research
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.
Rampotas A. et al, (2021), Ther Adv Hematol, 12
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Mughal TI. et al, (2020), Hematol Oncol, 38, 654 - 664
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Straus D. et al, (2020), Leuk Lymphoma, 61, 2931 - 2938
TARGET-Seq: A Protocol for High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Rodriguez-Meira A. et al, (2020), STAR protocols, 1, 100125 - 100125
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT. et al, (2020), Blood Adv, 4, 5825 - 5835
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Noy A. et al, (2020), Blood Adv, 4, 5773 - 5784